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continuous outcome measures and clinical
significance of results in randomized trials of
non-pharmacological interventions
Tammy C Hoffmann1,2*, Sarah T Thomas1, Paul Ng Hung Shin1 and Paul P Glasziou1Abstract
Background: Reporting the scoring details of continuous outcome measures in randomized trials allows readers to
interpret the size of any effect of the intervention. This study aimed to determine, in a sample of randomized trials:
1) the completeness of reporting of scoring details for continuous outcome measures, and 2) whether trial authors
comment on the clinical significance of statistically significant trial results.
Methods: A descriptive analysis of randomized trials of non-pharmacological interventions published during 2009
in the six leading general medical journals (n = 138), and which used at least one continuous outcome measure
(n = 85). From each trial report, two authors independently extracted the following information about each continuous
outcome measure: the reporting of its scoring details, presentation of its results, and the reporting and justification of
the clinical significance of the results.
Results: Across the 84 trials, we identified 336 continuous outcome measures. A total of 146 (44%) were published
measures, 12 (4%) were adapted from published measures, 5 (1%) were developed for the trial, and 173 (51%) were
‘conventional measures’ for which scoring details are not necessary (such as weight). For 57 (35%) of the 163
non-conventional outcome measures no scoring details or reference to the outcome measure were provided in
the trial report. Of the 159 outcome measures with a statistically significant result, clinical significance was not
mentioned for 81 (51%) and was reported without any elaboration or justification for 39 (25%) of them.
Conclusions: Scoring details of continuous outcome measures used in this sample of randomized trials of
non-pharmacological interventions were incompletely reported, which hampers interpretation of a trial’s results.
Complete reporting of scoring details is important when considering the clinical significance of the results. When
deciding about an intervention, having this information may help clinicians in their conversations with patients
about the possible benefits and harms, and their size, of the intervention.
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Randomized trials are widely used to evaluate the effect-
iveness of an intervention. All randomized trials assess
endpoint variables using outcome measures, which en-
ables comparison of groups in the trial. These outcome
measures need to be carefully selected and reported as
they can influence the conclusions of the trial and the
usability of its results.
Outcomes can be either dichotomous (such as dead/
alive and readmitted/not readmitted) or continuous (such
as weight and level of pain). Some continuous outcomes
(such as height, length of stay, and blood pressure) are
likely to be familiar to most readers of trial reports and
their scoring requires minimal description. However, many
continuous outcomes are assessed using measures for
which interpretation of the results relies on having at least
some understanding of how the measure is scored, such as
the possible range of scores. Without this information,
understanding the meaning of an effect size is hampered.
For example, the clinical significance of a two-point reduc-
tion on a 10-point scale is very different to the clinical
significance of a two-point reduction on a 100-point scale.
Readers of trials can sometimes mistakenly assume
that clinical trial results which are statistically significant
are also clinically significant [1]. Providing sufficient
details about the scoring of continuous outcome mea-
sures allows readers to interpret the effect size of the
intervention and the clinical significance of the result,
as opposed to relying solely on the interpretation of the
authors. Adequate reporting of results, which includes
information such as confidence intervals of effect sizes,
can also help with deliberations about the clinical
meaningfulness of trial results.
Previous studies of the quality of continuous outcome
measure reporting have primarily focussed on publication
bias [2,3] and the suitability and reporting of the psychomet-
ric properties of the measures [4,5]. The reporting of scoring
and interpretation details for continuous outcome measures
in randomized trials has not been investigated. This study
aimed to determine, in a sample of randomized trials of
non-pharmacological interventions: 1) the completeness
of reporting of scoring details for continuous outcome
measures, and 2) whether trial authors comment on the
clinical significance of statistically significant trial results.
Methods
Design
We performed a descriptive cross-sectional analysis of
randomized controlled trials which used at least one
continuous outcome measure.
Search strategy and selection of reports of trials
Trials were screened for eligibility from a previously
collected sample [6] of reports of randomized controlledtrials of non-pharmacological interventions published in
2009 in one of the six leading general medical journals
(based on ISI Web of Knowledge Impact Factor for
2010) - New England Journal of Medicine, the Journal of
the American Medical Association, Lancet, Annals of
Internal Medicine, PLOS Medicine, and the British Med-
ical Journal. An experienced medical librarian searched
PubMed in April 2011, using the restrictions of year
(2009), publication type (‘randomized controlled trial’),
and journal title (the six chosen journals). We supple-
mented our electronic search by hand-searching the table
of contents for these journals for 2009. Two authors (TH
and PG) screened the 358 titles and abstracts retrieved,
identified reports that might meet the inclusion criteria,
and retrieved the full-text (n = 138). From this sample, the
full-text of each trial was examined by two authors (BNHS
and ST) and all trials which had used at least one continu-
ous outcome measure were included (n = 84) in the
current study (for categories of interventions evaluated by
these trials, refer to Additional file 1: Table S1).
Data extraction and analysis
For each included trial, two authors (BNHS and ST)
independently extracted information about each con-
tinuous outcome measure using a data extraction form
developed in Microsoft Excel. Data were extracted as
to whether the outcome measure was: a specified primary
outcome measure; a published measure and if so, was a
citation provided and/or were scoring details provided in
the paper; a measure adapted from a published measure
and if so, were details of the adapted scoring provided; a
measure developed for the study and if so, were scoring
details provided; or a measure for which scoring details
are not necessary (such as length of stay or weight) and
referred to in this paper as a ‘conventional’ measure.
Throughout this paper, by scoring details we mean details
which assist in interpretation of the score (for example,
the total possible score, subscale scores where relevant,
score range, and/or explanation of the anchor points such
as whether a high score means better or worse). We do
not mean details about how to administer or score the
outcome measure or its psychometric properties. For each
measure for which scoring details were provided in the
paper, the location of this information in the paper was
recorded. Data about the summary measures (such as
mean or effect size) and precision estimates (such as
confidence intervals) used to report results were extracted
for all included outcome measures. Any words about
clinical significance (or related terms, such as ‘clinically
worthwhile’ or ‘minimum clinically important difference’)
were searched for in the PDF of each trial and recorded.
It was also noted which outcome this was referring to, if
a statistically significant effect (as defined by the trial
authors) had been reported for that outcome, and if any
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clinically significant was provided. Discrepancies between
raters were resolved by discussion and a consensus rater
(TH) was used when agreement could not be met. Data
were analysed descriptively.
Results
Categories of outcome measures and their scoring details
Across the 84 trials, a total of 336 continuous outcome
measures were used, with a mean of 4 continuous out-
come measures per trial (SD 2.6, range 1 to 11). Of these,
88 (26%) were specified as primary outcome measures,
245 (73%) were specified as secondary outcome measures,
and 3 (1%) were not classified as either by trial authors.
Half of all the outcome measures (173, 51%) and primary
outcome measures (45, 51%) were conventional measure-
ments for which reference or scoring details are not
required. Of the remaining 163 outcome measures, either
no scoring details or reference to the outcome measure
were provided for 57 (35%) of the measures (Figure 1).
For the 43 primary outcome measures, either no scoring
details or reference to the outcome measure were pro-
vided for 12 (28%) of the remaining (Figure 1). Of the 146
outcome measures that were reported to be a published
outcome measure, at least a reference to the measure was
provided for 140 (96%). Similarly, of the 40 primary
outcome measures which were a published measure, a
reference to the measure was provided for 39 (98%) of
them.
Below are some verbatim examples from papers where
outcome measures were listed and a reference provided, but
no scoring details or score interpretation were provided:0
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Figure 1 Number and percentage of published, adapted, and develop
(for all continuous outcome measures and for only primary outcome– In Methods: ‘Our secondary outcomes included the
state trait anxiety inventory [reference provided]…’. In
Results: ‘…61 (21%) women in the intervention group
had a score >44 on the state-trait anxiety inventory
compared with 86 (27%) in the control group…’
– In Methods: ‘We used the paediatric quality of life
inventory 4.0 (PedsQL(4.0) [reference provided] to
measure state of wellbeing or quality of life.’
– In Methods: ‘Secondary outcomes were … health
status (the short-form [SF-12] mental subscore)
[reference provided] and quality of life (the EuroQol
[EQ-5D]) [reference provided] analysed as continuous
variables at 4 and 8 months.’ In Results: ‘…adjustment
for baseline imbalance increased the comparisons
(e.g., for the SF-12 outcome the difference was then
4.0, 95% CI 0.1-8.0; p = 0.045).’
– In Methods: ‘The primary outcomes were the scores
on the Barthel index and the Rivermead mobility index
[reference provided]’ ‘A 2 point change on the Barthel
index was thought to be a meaningful change in
independence with respect to activities of daily living.’
In Abstract: ‘…no significant differences were found in
mean Barthel index scores at six months post-
randomisation between treatment arms (mean effect
0.08, 95% confidence interval −1.14 to 1.30; P = 0.90)…
Similarly, no significant differences were found in the
mean Rivermead mobility index scores between
treatment arms (0.62, −0.51 to 1.76; P = 0.28)…’
Location of scoring details in the paper
Table 1 shows where scoring details were located in the
paper when they were reported. For all measures andScoring details given
No scoring details given
2)  Primary (n=2)
d measures
All (n=5)   Primary (n=1)
Developed measures
ed outcome measures for which scoring details were provided
measures).
Table 1 Location of scoring details in the paper for
measures which reported scoring details
Location in paper All outcome
measures n = 106
Primary outcome
measures n = 31
Methods section 45 (42) 20 (65)
Results - in table, figure, or
footnote to these
35 (33) 2 (6)
In more than one place in
paper
33 (31) 12 (39)
Abstract 3 (3) 2 (6)
Discussion section 2 (2) 1 (3)
Results are presented as numbers (percentages).
Totals are >100% as location was more than one place in some papers.
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most often found in the methods section (37% and 54%
respectively) of the paper.
Reporting of results
For 238 (71%) of the outcome measures, a mean and a
measure of variance (such as standard deviation) was
reported. For 11 (3%) of the measures, only an effect size
was reported. Confidence intervals were reported as part
of the results for 237 (71%) of all outcome measures and
for 73 (83%) of the 88 primary outcome measures.
Reporting of the clinical significance of the results
A statistically significant result was reported for 159 (47%)
of the 336 continuous outcome measures and 61 (75%) of
the 88 primary outcome measures. For these measures,
Table 2 shows whether there was any comment about the
clinical significance of these results in the trial report and
if so, any elaboration about how clinical significance
was determined. There was no comment on clinical sig-
nificance for 51% of all outcome measures and 30% of
primary outcome measures. Following are two verbatim
examples which discuss clinical significance with some
justification of these:Table 2 Reporting and elaboration of clinical significance
of results which were reported as statistically significant
Reporting of clinical
significance of
statistically
significant results
All outcome
measures reporting
a statistically
significant result
n = 159
Primary outcomes
reporting a
statistically
significant result
n = 61
Clinical significance
commented on and
reference or justification
provided
39 (25) 26 (43)
Clinical significance
commented on, no
justification provided
39 (25) 17 (28)
No comment on clinical
significance of results
81 (51) 18 (30)
Results are presented as numbers (percentages).– Example 1 [7]: ‘The minimal clinically important
difference for Roland Morris Disability
Questionnaire (RMDQ) score ranges from 2 to 8
and is dependent on baseline score.17,51,52 The
minimal clinically important difference for RMDQ
score may be as low as 2 for subpopulations with
high rates of chronicity,52 as would be the case with
our patient population.’
– Example 2 [8]: ‘Minimally clinically important
differences…have been estimated for several of the
outcome measures used in this study.[…] estimated
minimally clinically important differences have ranged
between 3.5 and 4.3 points for the SF-36 PCS,25 1.0
and 2.5 points for back pain,15,25 and between 2 and 3
points for the Roland–Morris scale.16 The SF-36
physical function and EQ-5D estimates are 15 and
0.08 points, respectively.26,27’
For 177 outcome measures, the authors reported that
the results were not statistically significant, and for 10 of
these (eight trials), the trials contained a comment about
the clinical significance or meaningfulness of these results.
For seven measures, the comment appropriately referred
to between-group differences (including confidence inter-
vals of the difference) and the absence of a clinically
meaningful difference between the trial’s groups. For three
measures, comments referred to within-group changes
as being clinically meaningful (despite between-group
differences that were not statistically significant).
Discussion
In this study, we identified 336 continuous outcome
measures across 85 randomized trials of non-drug inter-
ventions and found incomplete reporting of scoring details
of outcome measures and clinical significance. Scoring
details were not given for 35% of all non-conventional
outcome measures. Clinical significance was not men-
tioned, or reported without justification, for 76% of all the
outcome measures that had a statistically significant result.
The strengths of this study include the wide range of
non-drug interventions and outcome measures in the
sample of included papers and the independent data
extraction by two assessors. A limitation is that the sample
of trials only included non-pharmacological interventions
and our findings may not extend to trials of pharmaco-
logical interventions. Our sample of trials was drawn from
the top six general medical journals and as the quality of
reporting is generally better in these journals [9], our
study is therefore likely to have underestimated the size of
the problem. Our sample of trials was from 2009 and so
reporting quality may have changed since then, although
there have been no explicit strategies since then that
have been aimed at improving the reporting of continu-
ous outcome measures that we are aware of. Additional
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measures and their scoring in a broader sample of trials
would enable further understanding of the extent of
this problem. Another limitation is that we did not
check whether the published references provided for
outcome measures did indeed contain scoring details.
Finally, we only recorded whether authors had provided a
justification for their interpretation of clinical significance,
we did not assess whether the justification was appropri-
ate. Likewise, we did not assess the risk of bias in each
trial and whether authors’ claim of statistical significance
were appropriate.
To the best of our knowledge, this is the first study
specifically looking at the reporting of scoring details of
continuous outcome measures in randomized trials.
Reporting of clinical significance has been analysed in a
small number of studies [10-13], with under-reporting
found. Chan et al. [10] analyzed the reporting of clinical
significance in a randomly selected sample of 27 random-
ized trials, which consisted of a mixture of pharmacological
and non-pharmacological interventions. The categories of
outcome measures (such as continuous or other) that were
used in their included trials are not described. They found
that clinical significance was mentioned in 20 (74%) trial
reports, with trial authors not providing a justification for
their clinical interpretation in most (15, 75%) of these [10].
Chan et al. also assessed the quality of reporting of factors
related to clinical significance (such as clearly defined
primary outcome and reporting of confidence intervals)
and concluded that authors often fail to report sufficient
information that would allow readers to interpret the
study results from their own perspective. For example,
confidence intervals were reported for only 41% of pri-
mary outcomes. In a systematic review of pharmacological
interventions for dementia, it was found that only 46% of
the 57 included randomized trials discussed the clinical
significance of the results [12].
Incomplete reporting restricts the usability of pub-
lished research and contributes to the problem of waste
in research [14]. If scoring details are not provided for
published measures, it is, at best, inconvenient as the
research user needs to look up the scoring details in the
cited reference or independently locate the reference for
the measure. While this does not render the research
unusable, it does slow down the process of using evidence
and introduces an unnecessary obstacle for the evidence
user. However, if no scoring details are provided for
adapted or newly developed measures, the only way to
obtain the missing information is by contacting trial
authors. This is a time-consuming step which few clini-
cians have time to undertake and for which a response
is not guaranteed. Without this complete information,
the reader is unable to fully interpret the results of the
study.The CONSORT (Consolidated Standards of Reporting
Trials) statement was developed to guide authors on
reporting the details of a randomized trial [15]. When
the trials included in this study were published, the
available CONSORT statement was the 2001 version. It
states in Item 6A (clearly defined primary and secondary
outcomes): ‘Where available and appropriate, previously
developed and validated scales or consensus guidelines
should be used… Authors should indicate the proven-
ance and properties of scales’ [16]. In the elaboration of
this item, it advocates for the use of published or existing
measures. However, it does not explicitly advise authors of
trials to provide scoring details of the measure in the
paper. The lack of specific instruction to do so may be
contributing to the incomplete reporting of such details
by authors. In the revised 2010 CONSORT statement [15],
there has been some minor rewording of Item 6A and it
now states that: ‘Completely defined pre-specified primary
and secondary outcome measures’ should be reported,
‘including how and when they were assessed’. However, it
is not clear whether ’completely defined’ also encompasses
scoring details and/or ranges for continuous outcome
measures.
The clinical meaning of intervention effects cannot be
ascertained by the researcher alone, and, as some argue,
nor by the clinician alone. Extrapolating the clinical
meaning of a result requires careful consideration of the
benefits of the intervention versus the possible burden
on the patient, and this balance varies from one patient
to another [17]. Various methods of determining clinical
significance have been proposed [18,19] but there is no
consensus on the ideal method of doing this. For many
interventions, the minimal clinically important difference
(MCID) that is considered acceptable varies between
patients [20] and between patients and clinicians [21].
Various terms (such as clinical significance, clinical
meaningfulness, clinically worthwhile, and MCID) are
also used interchangeably which can further complicate
interpretations of results that are made by authors. In
many situations, it may be that a patient-centred approach
to determining the clinical meaningfulness of a result is
best. In this approach, the possible benefits of the inter-
vention, as well as their size or likelihood are communi-
cated to patients, along with any possible harms (and their
size or likelihood), costs, and inconveniences of the
intervention. Only then can patients have an informed
discussion with their clinician about whether the likely
benefit from the intervention outweighs the likely harm
to an extent that is acceptable to them. Importantly, this
shared decision-making approach also enables incorpor-
ation of the patient’s preferences and values into the
discussion, with each patient approaching and managing
the benefit-harm trade-off of a decision differently. Com-
plete reporting of scoring details of continuous outcome
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information about the likely size of an intervention’s benefit
and/or harm when discussing a particular intervention
with patients.
Conclusions
The scoring details of some continuous outcome mea-
sures used in this sample of randomized trials of non-
pharmacological interventions in general medical journals
were incompletely reported. Authors of trials should en-
sure that measures and their scoring details are described
in sufficient detail in the trial report to facilitate interpret-
ation of the results. This additionally enables clinicians
to have this information at hand when considering the
clinical significance of the results. When deciding about
an intervention, this information may assist clinicians
in their conversations with patients about the possible
benefits and harms, and their size, of the intervention.
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Additional file 1: Table S1. Categories of interventions evaluated in
sample of trials (n = 84).
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